Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the successful close of Sofinnova Digital Medicine I at $200 million (€190M), significantly exceeding its target. The fund, spearheaded by Partners Edward Kliphuis and Simon Turner, is dedicated to backing pioneering entrepreneurs navigating the convergence of biology, data, and computation, and has already made investments into five revolutionary companies since its inception.
Antoine Papiernik, Sofinnova’s Chairman and Managing Partner, said: “The successful closing of Sofinnova Digital Medicine I above its target size marks yet another milestone in our growth as a global firm fostering disruptive innovations in life sciences. This newest fund in our platform of investment strategies is a testament to the trust our limited partners place in our vision and to Sofinnova’s longstanding commitment to shaping the future of healthcare.”
Sofinnova’s Digital Medicine Strategy comes at a pivotal moment when the healthcare sector is undergoing a significant transformation, aided by digital advancements. The fund targets three main areas: enabling technologies, analytics, and treatment. It provides entrepreneurs with financial backing, expertise, and deeply-rooted healthcare networks, empowering them to address global healthcare challenges and enhance patient outcomes worldwide.
The two most recent additions to the Sofinnova Digital Medicine portfolio include: L’école AI, creator of a “machine teaching” technology and established by an ex-Twitter Cortex founding team member, simplifies the deployment of deep-learning systems for computer vision in life sciences applications. Betteromics, the “Omics AI Cloud,” unifies disparate health and omics data into a single source of truth through a certified SaaS platform, backed by the expertise of its founding team from GRAIL, Verily and Google’s Search Knowledge Graph.
Edward Kliphuis, Partner, said: “In just a few months since launching this strategy, we’ve executed five investments into transformative companies, including Kiro, BioCorteX, deepc, L’école AI, and Betteromics, which are fusing state-of-the-art computational methods with advanced biological innovations. Leveraging Sofinnova’s expertise and network, we serve as allies to digital medicine pioneers, enabling them to secure product-market fit and scale on a global stage.”
Simon Turner, Partner, said: “We bring Sofinnova’s deep healthcare expertise to entrepreneurs pioneering at the forefront of digital medicine where biology meets tech-industry approaches like rapid product iteration and accelerated commercialization. Our goal is to support innovators developing disruptive solutions for patients and health systems.”
Also Read:
AMPECO raises USD 16 mln in venture capital investment
Veza secures strategic investments from Capital One Ventures and ServiceNow Ventures
